MedPath

Different therapies other than Sorafenib in TACE-refractory or TACE-failure advanced hepatocellular carcinoma: Safety and effectiveness

Not Applicable
Recruiting
Conditions
Hepatocellular carcinoma
Registration Number
JPRN-UMIN000005848
Lead Sponsor
Kyoto university hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

1.Patients with contraindiation for the use of the drugs

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
progression free survival
Secondary Outcome Measures
NameTimeMethod
time to progression, time to treatment failure, overall survival, response rate, disease control rate, safety
© Copyright 2025. All Rights Reserved by MedPath